Gamma interferon release assays for detection of Mycobacterium tuberculosis infection

Clinical Microbiology Reviews

Volumn 27, Issue 1, 2014, Pages 3-20

  Pai, Madhukar ^a   Denkinger, Claudia M ^a,b   Kik, Sandra V ^a   Rangaka, Molebogeng X ^c   Zwerling, Alice ^d   Oxlade, Olivia ^e   Metcalfe, John Z ^f   Cattamanchi, Adithya ^f   Dowdy, David W ^d   Dheda, Keertan ^g   Banaei, Niaz ^h  

^a MCGILL UNIVERSITY   (Canada)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; ISONIAZID; PLACEBO; TOLL LIKE RECEPTOR;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; BCG VACCINATION; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; META ANALYSIS (TOPIC); MONITORING; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RISK; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS;

HUMANS; IMMUNOLOGIC TESTS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 84891700498     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00034-13     Document Type: Article

References (137)

1. World Health Organization. 2013. Global tuberculosis control: WHO report 2013. WHO, Geneva, Switzerland.
2. Barry CE, 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-855. http://dx.doi.org/10.1038/nrmicro2236.
3. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. 2010. The immunology of tuberculosis: from bench to bedside. Respirology 15: 433-450. http://dx.doi.org/10.1111/j.1440-1843.2010.01739.x.
4. Landry J, Menzies D. 2008. Preventive chemotherapy. Where has it got us? Where to go next? Int. J. Tuberc. Lung Dis. 12:1352-1364.
5. American Thoracic Society. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161: S221-S247. http://dx.doi.org/10.1164/ajrccm.161.supplement_3.ats600.
6. Menzies RI. 2000. Tuberculin skin testing, p 279-322. In Reichman LB, Hershfield ES (ed), Tuberculosis: a comprehensive international approach. Marcel Dekker, New York, NY.
7. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, Pai M. 2011. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low-and middle-income countries: systematic review and meta-analysis. J. Infect. Dis. 204(Suppl 4):S1120-S1129. http://dx.doi.org/10.1093/infdis/jir410.
8. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, Bossink A, Dheda K, Diel R, Dominguez J, Lipman M, Nemeth J, Ravn P, Winkler S, Huitric E, Sandgren A, Manissero D. 2011. Interferongamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37:100-111. http://dx.doi.org /10.1183/09031936.00114810.
9. Deck F, Guld J. 1964. The WHO tuberculin test. Bull. Int. Union Tuberc. 34:53-70.
10. Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M. 2008. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int. J. Tuberc. Lung Dis. 12:498-505.
11. Farhat M, Greenaway C, Pai M, Menzies D. 2006. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int. J. Tuberc. Lung Dis. 10:1192-1204.
12. Zwerling A, Behr M, Varma A, Brewer TF, Menzies D, Pai M. 2011. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 8:e1001012. http://dx.doi.org/10.1371/journal.pmed.1001012.
13. Menzies D. 1999. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am. J. Respir. Crit. Care Med. 159:15-21. http://dx.doi.org/10.1164/ajrccm.159.1.9801120.
14. Watkins RE, Brennan R, Plant AJ. 2000. Tuberculin reactivity and the risk of tuberculosis: a review. Int. J. Tuberc. Lung Dis. 4:895-903.
15. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. 1996. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178:1274-1282.
16. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. 1995. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 63:1710-1717.
17. Andersen P, Munk ME, Pollock JM, Doherty TM. 2000. Specific immune-based diagnosis of tuberculosis. Lancet 356:1099-1104. http: //dx.doi.org/10.1016/S0140-6736(00)02742-2.
18. Geluk A, van Meijgaarden KE, Franken KL, Subronto YW, Wieles B, Arend SM, Sampaio EP, de Boer T, Faber WR, Naafs B, Ottenhoff TH. 2002. Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect. Immun. 70:2544-2548. http://dx.doi.org/10.1128 /IAI.70.5.2544-2548.2002.
19. Geluk A, van Meijgaarden KE, Franken KL, Wieles B, Arend SM, Faber WR, Naafs B, Ottenhoff TH. 2004. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis. Scand. J. Immunol. 59:66-70. http://dx.doi.org /10.1111/j.0300-9475.2004.01358.x.
20. Pai M, Riley LW, Colford JM, Jr. 2004. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4:761-776. http://dx.doi.org/10.1016/S1473-3099(04)01206-X.
21. Pai M, Zwerling A, Menzies D. 2008. T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149:177-184. http://dx.doi.org/10.7326/0003-4819-149-3-200808050-00241.
22. Santin M, Munoz L, Rigau D. 2012. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIVinfected adults: a systematic review and meta-analysis. PLoS One 7:e32482. http://dx.doi.org/10.1371/journal.pone.0032482.
23. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. 2011. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 15:1018-1032. http://dx.doi.org/10.5588/ijtld.10.0631.
24. Zwerling A, Pai M. 2011. The BCG world atlas: a new, open-access resource for clinicians and researchers. Expert Rev. Anti Infect. Ther. 9:559-561. http://dx.doi.org/10.1586/eri.11.71.
25. Arend SM, van Meijgaarden KE, de Boer K, de Palou EC, van Soolingen D, Ottenhoff TH, van Dissel JT. 2002. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J. Infect. Dis. 186:1797-1807. http://dx.doi.org/10.1086/345760.
26. Lewis FM, Marsh BJ, von Reyn CF. 2003. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin. Infect. Dis. 37:390-397. http: //dx.doi.org/10.1086/376628.
27. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, Reingold AL, Colford JM, Jr, Riley LW, Menzies D. 2006. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am. J. Respir. Crit. Care Med. 174:349-355. http://dx.doi.org/10.1164 /rccm.200604-472OC.
28. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. 2009. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 4:e8517. http://dx.doi.org/10.1371/journal.pone.0008517.
29. Herrera V, Perry S, Parsonnet J, Banaei N. 2011. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin. Infect. Dis. 52:1031-1037. http://dx.doi.org/10.1093/cid/cir068.
30. Slater M, Parsonnet J, Banaei N. 2012. Investigation of false-positive results given by the QuantiFERON-TB Gold In-Tube assay. J. Clin. Microbiol. 50:3105-3107. http://dx.doi.org/10.1128/JCM.00730-12.
31. Cellestis-Qiagen Inc. 2012. Notification of market withdrawal of QuantiFERON®-TB Gold (QFT®)TB-Antigen blood collection tubes-lot # A111103N and lot # A111103M (high altitude). http://public.health.oregon.gov/LaboratoryServices/Documents/qft-notice.pdf. Accessed 7 August 2013.
32. Doberne D, Gaur RL, Banaei N. 2011. Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection. J. Clin. Microbiol. 49:3061-3064. http://dx.doi.org/10.1128/JCM.01136-11.
33. Shanaube K, De Haas P, Schaap A, Moyo M, Kosloff B, Devendra A, Raby E, Godfrey-Faussett P, Ayles H. 2010. Intra-assay reliability and robustness of QuantiFERON(R)-TB Gold In-Tube test in Zambia. Int. J. Tuberc. Lung Dis. 14:828-833.
34. Gaur R, Pai M, Banaei N. 2013. Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB Gold In-Tube assay. J. Clin. Microbiol. 51:3521-3526. http://dx.doi.org/10.1128 /JCM.01627-13.
35. Whitworth WC, Mazurek GH, Goodwin DJ. 2012. Assay parameters affecting variability of QuantiFERON-TB Gold In-Tube assay results, p A4728, C61. In Immunodiagnostics for latent tuberculosis infection and tuberculosis. American Thoracic Society, New York, NY.
36. Mazurek GH, Whitworth WC, Goodwin DJ. 2012. Effect of blood collection time on QuantiFERON-TB Gold In-Tube test variability, p A4735, C61. In Immunodiagnostics for latent tuberculosis infection and tuberculosis. American Thoracic Society, New York, NY.
37. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. 2013. Test variability of the QuantiFERON-TB Gold In-Tube assay in clinical practice. Am. J. Respir. Crit. Care Med. 187:206-211. http://dx.doi.org/10.1164/rccm.201203-0430OC.
38. Whitworth WC, Hamilton LR, Goodwin DJ, Barrera C, West KB, Racster L, Daniels LJ, Chuke SO, Campbell BH, Bohanon J, Jaffar AT, Drane W, Maserang D, Mazurek GH. 2012. Within-subject interlaboratory variability of QuantiFERON-TB Gold In-Tube tests. PLoS One 7:e43790. http://dx.doi.org/10.1371/journal.pone.0043790.
39. Franken WP, Thijsen S, Wolterbeek R, Bouwman JJ, El Bannoudi H, Kik SV, van Dissel JT, Arend SM. 2009. Variation in T-SPOT. TB spot interpretation between independent observers from different laboratories. Clin. Vaccine Immunol. 16:1439-1442. http://dx.doi.org/10.1128 /CVI.00456-08.
40. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, Dheda K. 2009. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am. J. Respir. Crit. Care Med. 180:49-58. http: //dx.doi.org/10.1164/rccm.200811-1704OC.
41. Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montane E, Singh M, Spallek R, Ausina V, Cardona PJ. 2008. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand. J. Immunol. 67:610-617. http://dx.doi.org/10.1111/j.1365-3083.2008.02103.x.
42. Naseer A, Naqvi S, Kampmann B. 2007. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing. Eur. Respir. J. 29:1282-1283. http://dx.doi.org/10.1183/09031936.00017807.
43. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee MK. 2008. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest 133:1415-1420. http://dx.doi.org/10.1378/chest.07-2193.
44. Igari H, Watanabe A, Sato T. 2007. Booster phenomenon of QuantiFERON-TB Gold after prior intradermal PPD injection. Int. J. Tuberc. Lung Dis. 11:788-791.
45. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N. 2012. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am. J. Respir. Crit. Care Med. 185:213-222. http://dx.doi.org/10.1164/rccm.201104-0714OC.
46. Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, Ajassa C, Vullo V, Mastroianni CM. 2011. Influence of previous tuberculin skin test on serial IFN-gamma release assays. Tuberculosis (Edinb.) 91:322-326. http://dx.doi.org/10.1016/j.tube.2011.05.004.
47. Mogensen TH. 2009. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22:240-273. http://dx.doi.org/10.1128/CMR.00046-08.
48. Gaur RL, Suhosk MM, Banaei N. 2012. In vitro immunomodulation of a whole blood IFN-gamma release assay enhances T cell responses in subjects with latent tuberculosis infection. PLoS One 7:e48027. http://dx.doi.org/10.1371/journal.pone.0048027.
49. Pai M. 2012. Serial testing with TB interferon-gamma release assays: toward a nuanced understanding. Chest 142:1366-1367. http://dx.doi.org/10.1378/chest.12-1208.
50. Fan L, Chen Z, Hao XH, Hu ZY, Xiao HP. 2012. Interferon-gamma release assays for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. FEMS Immunol. Med. Microbiol. 65: 456-466. http://dx.doi.org/10.1111/j.1574-695X.2012.00972.x.
51. Pai M, Menzies D. 2007. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? Clin. Infect. Dis. 44:74-77. http://dx.doi.org/10.1086/509927.
52. Dheda K, van Zyl Smit R, Badri M, Pai M. 2009. T-cell interferongamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr. Opin. Pulm. Med. 15:188-200. http://dx.doi.org/10.1097/MCP.0b013e32832a0adc.
53. World Health Organization. 2011. Policy statement: use of tuberculosis interferon-gamma release assays (IGRAs) in low-and middle-income countries. World Health Organization, Geneva, Switzerland.
54. Rangaka MX, Gideon HP, Wilkinson KA, Pai M, Mwansa-Kambafwile J, Maartens G, Glynn JR, Boulle A, Fielding K, Goliath R, Titus R, Mathee S, Wilkinson RJ. 2012. Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. Eur. Respir. J. 39:163-171. http://dx.doi.org/10.1183/09031936.00058911.
55. Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P. 2010. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Am. J. Respir. Crit. Care Med. 181:87-93. http://dx.doi.org/10.1164/rccm.200906-0981OC.
56. Ling DI, Pai M, Davids V, Brunet L, Lenders L, Meldau R, Calligaro G, Allwood B, van Zyl-Smit R, Peter J, Bateman E, Dawson R, Dheda K. 2011. Are interferon-gamma release assays useful for diagnosing active tuberculosis in a high-burden setting? Eur. Respir. J. 38:649-656. http://dx.doi.org/10.1183/09031936.00181610.
57. Ling DI, Nicol M, Pai M, Pienaar S, Dendukuri N, Zar HJ. 2013. Incremental value of T-SPOT. TB for diagnosis of active pulmonary tuberculosis in children in a high-burden setting: a multivariable analysis. Thorax 68:860-866. http://dx.doi.org/10.1136/thoraxjnl-2012-203086.
58. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. 2006. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am. J. Respir. Crit. Care Med. 173:1078-1090. http://dx.doi.org/10.1164 /rccm.200511-1809SO.
59. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, Hanekom W, Mahomed H. 2011. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr. Infect. Dis. J. 30:694-700. http://dx.doi.org/10.1097/INF.0b013e318214b915.
60. Kakkar F, Allen U, Ling D, Pai M, Kitai I. 2010. Tuberculosis in children: new diagnostic blood tests. Paediatr. Child Health 15:529-538.
61. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell PC, Pai M. 2011. Interferongamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals-a systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr. 56:230-238. http://dx.doi.org/10.1097/QAI.0b013e31820b07ab.
62. Chen J, Zhang R, Wang J, Liu L, Zheng Y, Shen Y, Qi T, Lu H. 2011. Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: a systematic review and meta-analysis. PLoS One 6:e26827. http://dx.doi.org/10.1371/journal.pone.0026827.
63. Winthrop KL, Weinblatt ME, Daley CL. 2012. You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann. Rheum. Dis. 71: 1757-1760. http://dx.doi.org/10.1136/annrheumdis-2012-201979.
64. Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, Pai M. 2011. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr. Opin. Rheumatol. 23:377-384. http://dx.doi.org/10.1097/BOR.0b013e3283474d62.
65. Shahidi N, Fu YT, Qian H, Bressler B. 2012. Performance of interferongamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm. Bowel Dis. 18:2034-2042. http://dx.doi.org/10.1002/ibd.22901.
66. Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, Kang ES, Koh WJ. 2011. Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin. Rheumatol. 30:1535-1541. http://dx.doi.org/10.1007/s10067-011-1771-9.
67. Winthrop KL. 2010. The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy. Int. J. Adv. Rheumatol. 8:43-52.
68. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. 2012. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 67:62-70. http://dx.doi.org/10.1136/thx.2010.143180.
69. Ringshausen FC, Schablon A, Nienhaus A. 2012. Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. J. Occup. Med. Toxicol. 7:6. http://dx.doi.org/10.1186 /1745-6673-7-6.
70. Zwerling A, Benedetti A, Cojocariu M, McIntosh F, Pietrangelo F, Behr M, Schwartzman K, Menzies D, Pai M. 2013. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 8:e54748. http://dx.doi.org/10.1371/journal.pone.0054748.
71. Fong KS, Tomford JW, Teixeira L, Fraser TG, van Duin D, Yen-Lieberman B, Gordon SM, Miranda C. 2012. Challenges of interferongamma release assay conversions in serial testing of health-care workers in a TB control program. Chest 142:55-62. http://dx.doi.org/10.1378 /chest.11-0992.
72. Gandra S, Scott WS, Somaraju V, Wang H, Wilton S, Feigenbaum M. 2010. Questionable effectiveness of the QuantiFERON-TB Gold test (Cellestis) as a screening tool in healthcare workers. Infect. Control Hosp. Epidemiol. 31:1279-1285. http://dx.doi.org/10.1086/657336.
73. Joshi M, Monson TP, Woods GL. 2012. Use of interferon-gamma release assays in a health care worker screening program: experience from a tertiary care centre in the United States. Can. Respir. J. 19:84-88.
74. Thanassi W, Noda A, Hernandez B, Newell J, Terpeluk P, Marder D, Yesavage JA. 2012. Delineating a retesting zone using receiver operating characteristic analysis on serial QuantiFERON tuberculosis test results in US healthcare workers. Pulm. Med. 2012:291294. http://dx.doi.org/10.1155/2012/291294.
75. Rafiza S, Rampal KG. 2012. Serial testing of Malaysian health care workers with QuantiFERON(R)-TB Gold In-Tube. Int. J. Tuberc. Lung Dis. 16:163-168. http://dx.doi.org/10.5588/ijtld.11.0364.
76. Torres Costa J, Silva R, Sa R, Cardoso MJ, Nienhaus A. 2011. Serial testing with the interferon-gamma release assay in Portuguese healthcare workers. Int. Arch. Occup. Environ. Health 84:461-469. http://dx.doi.org/10.1007/s00420-010-0571-x.
77. Schablon A, Harling M, Diel R, Ringshausen FC, Torres Costa J, Nienhaus A. 2010. Serial testing with an interferon-γ release assay in German healthcare workers. GMS Krankenhhyg. Interdiszip. 5:Doc05. http://dx.doi.org/10.3205/dgkh000148.
78. Ringshausen FC, Nienhaus A, Schablon A, Schlosser S, Schultze-Werninghaus G, Rohde G. 2010. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect. Dis. 10:220. http: //dx.doi.org/10.1186/1471-2334-10-220.
79. Park HY, Jeon K, Suh GY, Kwon OJ, Chung DR, Yoonchang SW, Kang ES, Koh WJ. 2010. Interferon-gamma release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital. Scand. J. Infect. Dis. 42:943-945. http://dx.doi.org/10.3109/00365548.2010.524658.
80. Lee K, Han MK, Choi HR, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Woo JH, Shim TS. 2009. Annual incidence of latent tuberculosis infection among newly employed nurses at a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30:1218-1222. http://dx.doi.org /10.1086/648082.
81. Chee CB, Lim LK, Barkham TM, Koh DR, Lam SO, Shen L, Wang YT. 2009. Use of a T cell interferon-gamma release assay to evaluate tuberculosis risk in newly qualified physicians in Singapore healthcare institutions. Infect. Control Hosp. Epidemiol. 30:870-875. http://dx.doi.org /10.1086/599284.
82. Yoshiyama T, Harada N, Higuchi K, Nakajima Y, Ogata H. 2009. Estimation of incidence of tuberculosis infection in health-care workers using repeated interferon-gamma assays. Epidemiol. Infect. 137:1691-1698. http://dx.doi.org/10.1017/S0950268809002751.
83. Pollock NR, Campos-Neto A, Kashino S, Napolitano D, Behar SM, Shin D, Sloutsky A, Joshi S, Guillet J, Wong M, Nardell E. 2008. Discordant QuantiFERON-TB Gold test results among US healthcare workers with increased risk of latent tuberculosis infection: a problem or solution? Infect. Control Hosp. Epidemiol. 29:878-886. http://dx.doi.org/10.1086/590262.
84. Park JS, Lee JS, Kim MY, Lee CH, Yoon HI, Lee SM, Yoo CG, Kim YW, Han SK, Yim JJ. 2012. Monthly follow-ups of interferon-gamma release assays among healthcare workers in contact with TB patients. Chest 142:1461-1468. http://dx.doi.org/10.1378/chest.11-3299.
85. Joshi M, Monson T, Woods G. 2012. Performance and practicality of IGRA in serial testing for latent TB infection in US healthcare workers-a real world experience. Chest 142:142A. http://dx.doi.org/10.1378/chest.1386337.
86. Dorman S, Belknap R, Graviss EA, Reeves R, Schulger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter L, Parker M, Garrett DO, Daley CL. 3 December 2013. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am. J. Respir. Crit. Care Med. [Epub ahead of print.] http://dx.doi.org/10.1164/rccm.201302-0365OC.
87. Slater M, Welland G, Pai M, Parsonnet J, Banaei N. 2013. Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers. Am. J. Respir. Crit. Care Med. 188:1005-1010. http://dx.doi.org/10.1164/rccm.201305-0831OC.
88. Pai M. 2010. Spectrum of latent tuberculosis-existing tests cannot resolve the underlying phenotypes. Nat. Rev. Microbiol. 8:242. http://dx.doi.org/10.1038/nrmicro2236-c1.
89. Zwerling A, Joshi R, Kalantri SP, Dakshinamoorthy G, Reddy MVR, Benedetti A, Schwartzman K, Menzies D, Pai M. 2013. Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. J. Epidemiol. Glob. Health 3:105-117. http://dx.doi.org/10.1016/j.jegh.2013.03.003.
90. Pai M, Elwood K. 2012. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges. Can. Respir. J. 19:81-83. (Corrigendum, 19:186.).
91. Pai M, Banaei N. 2013. Occupational screening of health care workers for tuberculosis infection: tuberculin skin testing or interferon-γ release assays? Occup. Med. (Lond.) 63:458-460. http://dx.doi.org/10.1093 /occmed/kqt105.
92. Lalvani A. 2004. Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? Clin. Infect. Dis. 38: 757-759. http://dx.doi.org/10.1086/381763.
93. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. 2010. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920-1937. http://dx.doi.org/10.1016/S0140-6736(10)60359-5.
94. Katiyar SK, Sampath A, Bihari S, Mamtani M, Kulkarni H. 2008. Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:1146-1152.
95. Chee CB, KhinMar KW, Gan SH, Barkham TM, Koh CK, Shen L, Wang YT. 2010. Tuberculosis treatment effect on T-cell interferongamma responses to Mycobacterium tuberculosis-specific antigens. Eur. Respir. J. 36:355-361. http://dx.doi.org/10.1183/09031936.00151309.
96. Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, Chaisson RE, Conde MB, Boechat N, Dorman SE. 2009. T-SPOT. TB responses during treatment of pulmonary tuberculosis. BMC Infect. Dis. 9:23. http: //dx.doi.org/10.1186/1471-2334-9-23.
97. Theron G, Peter J, Lenders L, van Zyl-Smit R, Meldau R, Govender U, Dheda K. 2012. Correlation of Mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting. PLoS One 7:e37436. http://dx.doi.org/10.1371 /journal.pone.0037436.
98. Denkinger CM, Pai M, Patel M, Menzies D. 2013. Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. J. Clin. Microbiol. 51:607-610. http://dx.doi.org/10.1128/JCM.02278-12.
99. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. 2006. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 174:831-839. http://dx.doi.org/10.1164/rccm.200511-1783OC.
100. Higuchi K, Harada N, Mori T. 2005. Effect of prophylaxis on responses for ESAT-6/CFP-10 in whole blood IFN-g test. Eur. Respir. J. 26:22S.
101. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. 2007. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am. J. Respir. Crit. Care Med. 175:282-287. http://dx.doi.org/10.1164/rccm.200608-1109OC.
102. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, Kalantri S. 2006. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J. Occup. Med. Toxicol. 1:7. http://dx.doi.org /10.1186/1745-6673-1-7.
103. Adetifa IM, Ota MO, Jeffries DJ, Lugos MD, Hammond AS, Battersby NJ, Owiafe PK, Donkor SD, Antonio M, Ibanga HB, Brookes RH, Aka P, Walton R, Adegbola RA, Hill PC. 2013. Interferon-gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am. J. Respir. Crit. Care Med. 187:439-445. http://dx.doi.org/10.1164/rccm.201208-1352OC.
104. Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, de Martino M. 2012. Utility of interferon-gamma release assay results to monitor antitubercular treatment in adults and children. Clin. Ther. 34:1041-1048. http://dx.doi.org/10.1016/j.clinthera.2012.03.006.
105. Diel R, Loddenkemper R, Nienhaus A. 2012. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142:63-75. http://dx.doi.org/10.1378/chest.11-3157.
106. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. 2012. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 12:45-55. http: //dx.doi.org/10.1016/S1473-3099(11)70210-9.
107. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, Eguale T, Ravn P, Andersen P. 2002. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40:704-706. http: //dx.doi.org/10.1128/JCM.40.2.704-706.2002.
108. Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, Lugos MD, Adetifa IM, Donkor SA, Aiken AM, Howie SR, Corrah T, Mc-Adam KP, Adegbola RA. 2008. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 3:e1379. http://dx.doi.org/10.1371/journal.pone.0001379.
109. Bakir M, Millington KA, Soysal A, Deeks JJ, Efee S, Aslan Y, Dosanjh DP, Lalvani A. 2008. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann. Intern. Med. 149:777-787. http://dx.doi.org/10.7326/0003-4819-149-11-200812020-00248.
110. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. 2009. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin. Infect. Dis. 48:954-962. http://dx.doi.org/10.1086/597351.
111. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S. 2010. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur. Respir. J. 35:1346-1353. http://dx.doi.org/10.1183 /09031936.00098509.
112. del Corral H, Paris SC, Marin ND, Marin DM, Lopez L, Henao HM, Martizen T, Villa L, Barrera L, Ortiz BL, Ramirez ME, Montes CJ. 2009. IFNg response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 4:e8257. http://dx.doi.org/10.1371/journal.pone.0008257.
113. Lienhardt C, Fielding K, Hane AA, Niang A, Ndao CT, Karam F, Fletcher H, Mbow F, Gomis JF, Diadhiou R, Toupane M, Dieye T, Mboup S. 2010. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 5:e10508. http://dx.doi.org/10.1371/journal.pone.0010508.
114. Yoshiyama T, Harada N, Higuchi K, Sekiya Y, Uchimura K. 2010. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. Int. J. Tuberc. Lung Dis. 14:819-827.
115. Leung CC, Yam WC, Yew WW, Ho PL, Tam CM, Law WS, Au KF, Tsui PW. 2010. T-Spot. TB outperforms tuberculin skin test in predicting tuberculosis disease. Am. J. Respir. Crit. Care Med. 182:834-840. http://dx.doi.org/10.1164/rccm.200912-1875OC.
116. Harstad I, Winje BA, Heldal E, Oftung F, Jacobsen GW. 2010. Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. Int. J. Tuberc. Lung Dis. 14:1209-1211.
117. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. 2011. Negative and positive predictive value of a whole-blood interferon-gamma release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 183:88-95. http://dx.doi.org/10.1164 /rccm.201006-0974OC.
118. Jonnalagadda S, Lohman Payne B, Brown E, Wamalwa D, Maleche Obimbo E, Majiwa M, Farquhar C, Otieno P, Mbori-Ngacha D, John-Stewart G. 2010. Latent tuberculosis detection by interferon gamma release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children. J. Infect. Dis. 202:1826-1835. http://dx.doi.org/10.1086 /657411.
119. Joshi R, Narang U, Zwerling A, Jain D, Jain V, Kalantri S, Pai M. 2011. Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study. Eur. Respir. J. 38:1475-1477. http://dx.doi.org/10.1183 /09031936.00014611.
120. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, Ehrlich R, Hanekom WA, Hussey GD. 2011. The tuberculin skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 6:e17984. http://dx.doi.org/10.1371/journal.pone.0017984.
121. Torres Costa J, Silva R, Ringshausen FC, Nienhaus A. 2011. Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. J. Occup. Med. Toxicol. 6:19. http://dx.doi.org/10.1186/1745-6673-6-19.
122. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, Jung JH, Kim YH, Kim SC, Choi SH, Jeong JY, Kim YS, Woo JH, Park SK, Park JS, Han DJ. 2011. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am. J. Transplant. 11:1927-1935. http://dx.doi.org/10.1111/j.1600-6143.2011.03625.x.
123. Haldar P, Thuraisingam H, Patel H, Pereira N, Free RC, Entwisle J, Wiselka M, Hoskyns EW, Monk P, Barer MR, Woltmann G. 2013. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 68:240-246. http://dx.doi.org/10.1136/thoraxjnl-2011-200956.
124. Lange B, Vavra M, Kern WV, Wagner D. 2012. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int. J. Tuberc. Lung Dis. 16:492-495. http://dx.doi.org/10.5588/ijtld.11.0416.
125. Kim YJ, Kim SI, Kim YR, Wie SH, Park YJ, Kang MW. 2012. Predictive value of interferon-gamma ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. AIDS Res. Hum. Retroviruses 28:1038-1043. http://dx.doi.org/10.1089/AID.2011.0360.
126. Bergot E, Haustraete E, Malbruny B, Magnier R, Salaun MA, Zalcman G. 2012. Observational study of QuantiFERON(R)-TB Gold in-tube assay in tuberculosis contacts in a low incidence area. PLoS One 7:e43520. http://dx.doi.org/10.1371/journal.pone.0043520.
127. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H. 2012. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am. J. Respir. Crit. Care Med. 186:1051-1056. http://dx.doi.org/10.1164/rccm.201206-1134OC.
128. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. 2012. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54:784-791. http: //dx.doi.org/10.1093/cid/cir951.
129. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973-977. http://dx.doi.org/10.1038/nature09247.
130. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM. 2009. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 33:956-973. http: //dx.doi.org/10.1183/09031936.00120908.
131. Nienhaus A, Schablon A, Costa JT, Diel R. 2011. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv. Res. 11:247. http://dx.doi.org/10.1186/1472-6963-11-247.
132. Oxlade O, Pinto M, Trajman A, Menzies D. 2013. How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. PLoS One 8:e56044. http://dx.doi.org/10.1371/journal.pone.0056044.
133. Denkinger CM, Dheda K, Pai M. 2011. Guidelines on interferongamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin. Microbiol. Infect. 17:806-814. http://dx.doi.org/10.1111/j.1469-0691.2011.03555.x.
134. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm. Rep. 59:1-25.
135. Pai M, Kunimoto D, Jamieson F, Menzies D. 2013. Diagnosis of latent tuberculosis infection. Can. Respir. J. 20:23A-34A.
136. LoBue PA, Castro KG. 2012. Is it time to replace the tuberculin skin test with a blood test? JAMA 308:241-242. http://dx.doi.org/10.1001/jama.2012.7511.
137. Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M. 2012. Immunodiagnosis of tuberculosis: state of the art. Med. Princ. Pract. 21:4-13. http://dx.doi.org/10.1159/000331583.